Tacrolimus for Treating Orbital and Cranial Form of Idiopathic Inflammatory Pseudotumors

BACKGROUND AND PURPOSEOrbital and cranial form of idiopathic inflammatory pseudotumors (IIPs) are rare disorders with heterogeneous clinical presentations. Corticosteroids have been the first-line treatment for IIPs, but they are not always effective. METHODSWe reviewed the medical records of three...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical neurology (Seoul, Korea) Vol. 16; no. 4; pp. 674 - 680
Main Authors Kim, Hyun Jae, Lee, Seonkyung, Koo, Yu Jin, Kwon, Eunjin, Kim, Hyo-Jung, Choi, Jeong-Yoon, Kim, Ji-Soo
Format Journal Article
LanguageEnglish
Published Korean Neurological Association 01.10.2020
대한신경과학회
Subjects
Original
신경과학
Online AccessGet full text

Cover

More Information
Summary:BACKGROUND AND PURPOSEOrbital and cranial form of idiopathic inflammatory pseudotumors (IIPs) are rare disorders with heterogeneous clinical presentations. Corticosteroids have been the first-line treatment for IIPs, but they are not always effective. METHODSWe reviewed the medical records of three patients with orbital or cranial form of IIP who were treated with tacrolimus as an adjuvant treatment. RESULTSThe three patients showed favorable outcomes with the addition of tacrolimus, which is a calcineurin inhibitor that inhibits T-cell activation and T-cell-dependent B-cell activation. CONCLUSIONSTacrolimus may be a safe and effective immunosuppressant for refractory or relapsing form of orbital or cranial IIPs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
https://doi.org/10.3988/jcn.2020.16.4.674
ISSN:1738-6586
2005-5013
DOI:10.3988/jcn.2020.16.4.674